Type 2 Diabetes Mellitus
Type 2 diabetes mellitus is a chronic metabolic condition characterised by insulin resistance combined with progressive beta-cell dysfunction. Unlike Type 1 diabetes, insulin is initially present, and often elevated, but is unable to exert its normal metabolic effects. Over time, pancreatic insulin secretion becomes inadequate relative to the degree of resistance, resulting in persistent hyperglycaemia. Understanding the pathophysiology of Type 2 diabetes requires moving beyond the idea of “high blood sugar” to recognise it as a disorder of impaired cellular signalling, altered energy handling, and chronic metabolic stress affecting multiple organ systems.
What You Need to Know
Type 2 diabetes mellitus develops when target tissues, particularly skeletal muscle, adipose tissue, and the liver, become less responsive to insulin. This insulin resistance reduces glucose uptake into peripheral tissues and weakens insulin’s ability to suppress hepatic glucose production. Blood glucose levels therefore rise despite the continued presence of circulating insulin, distinguishing Type 2 diabetes from absolute insulin deficiency states.
In the early stages, pancreatic beta cells respond to insulin resistance by increasing insulin secretion. This compensatory hyperinsulinaemia may maintain near-normal glucose levels for a prolonged period, allowing the condition to remain clinically silent. During this phase, metabolic stress is already present at the cellular level, even though fasting glucose may appear only mildly elevated.
As insulin resistance persists, beta-cell function gradually declines. Chronic exposure to elevated glucose and fatty acids impairs insulin secretion and accelerates beta-cell dysfunction, reducing the capacity to compensate for insulin resistance. This transition is characterised by:
Reduced insulin sensitivity in muscle, liver, and adipose tissue
Compensatory hyperinsulinaemia maintaining early glycaemic stability
Progressive beta-cell dysfunction driven by glucotoxicity and lipotoxicity
Development of relative insulin deficiency with sustained hyperglycaemia
Once compensatory insulin secretion can no longer meet metabolic demand, hyperglycaemia becomes persistent. At this stage, both insulin resistance and impaired insulin secretion contribute to metabolic instability, setting the foundation for acute dysregulation and long-term vascular and neurological complications associated with Type 2 diabetes.
Beyond the Basics
Insulin resistance at the cellular level
Insulin resistance represents impaired intracellular signalling rather than absence of insulin. In skeletal muscle and adipose tissue, defects within insulin receptor signalling pathways reduce translocation of glucose transporters to the cell membrane. This limits glucose entry into cells, particularly after meals, and contributes to post-prandial hyperglycaemia even when insulin levels are elevated.
In the liver, insulin resistance prevents normal suppression of gluconeogenesis. Hepatic glucose production continues despite already elevated blood glucose, compounding hyperglycaemia. These tissue-specific effects explain why Type 2 diabetes involves both reduced peripheral glucose uptake and inappropriate endogenous glucose release at the same time.
Beta-cell compensation and failure
Early in the disease process, pancreatic beta cells increase insulin secretion in an attempt to overcome insulin resistance. This compensatory hyperinsulinaemia may delay overt hyperglycaemia for years but places sustained metabolic stress on beta cells. During this phase, insulin levels are high, yet metabolic control remains fragile.
Over time, beta-cell function deteriorates due to oxidative stress, inflammatory signalling, and accumulation of toxic lipid intermediates. As beta-cell reserve declines, insulin secretion becomes insufficient to meet metabolic demand. This transition from compensation to failure explains the gradual progression of Type 2 diabetes and why interventions that rely on preserved beta-cell function become less effective as the disease advances.
Glucotoxicity, lipotoxicity, and chronic metabolic injury
Persistent hyperglycaemia and elevated free fatty acids exert direct toxic effects on multiple tissues. Glucotoxicity impairs insulin secretion and further reduces insulin sensitivity, while lipotoxicity disrupts intracellular metabolism and promotes inflammatory pathways. These processes reinforce each other, creating a self-perpetuating cycle of worsening metabolic control.
At the vascular level, prolonged exposure to elevated glucose damages endothelial cells, impairs nitric oxide signalling, and accelerates atherosclerotic change. Microvascular circulation is also affected, reducing tissue perfusion and oxygen delivery. These mechanisms explain why Type 2 diabetes is closely linked to cardiovascular disease, nephropathy, neuropathy, and retinopathy, often developing silently long before diagnosis is established.
Clinical Connections
Clinical presentation in Type 2 diabetes arises from chronic hyperglycaemia driven by insulin resistance, with later contribution from relative insulin deficiency as beta-cell function declines. Because insulin is present, metabolic decompensation usually develops gradually rather than abruptly, allowing hyperglycaemia to remain unrecognised for long periods. This prolonged exposure to elevated glucose drives tissue injury before diagnosis and explains why complications may already be established at presentation.
Hyperglycaemia is the dominant metabolic disturbance in Type 2 diabetes. Insulin resistance limits glucose uptake in muscle and adipose tissue while hepatic glucose production continues despite elevated circulating glucose. Renal glucose excretion increases once the renal threshold is exceeded, leading to osmotic diuresis and progressive dehydration, particularly during illness or reduced intake.
Hyperglycaemia in Type 2 diabetes is commonly associated with:
Fatigue, blurred vision, recurrent infections, and delayed wound healing
Polyuria and dehydration during periods of poor intake or acute illness
Severe hyperglycaemia without ketosis, particularly in older adults
Elevated HbA1c, indicating prolonged exposure to high glucose and increased vascular risk
Hypoglycaemia can occur in Type 2 diabetes, most often as a consequence of glucose-lowering therapies rather than intrinsic disease physiology. As beta-cell function declines, endogenous insulin regulation becomes less responsive, and exogenous insulin or insulin secretagogues may exceed glucose availability, particularly with missed meals, weight loss, or reduced intake during illness.
Hypoglycaemia in Type 2 diabetes is commonly associated with:
Adrenergic symptoms such as tremor, sweating, and palpitations
Neuroglycopenic features including confusion, dizziness, or reduced consciousness
Increased risk in older adults and those with renal impairment
HbA1c that may appear acceptable despite significant glucose variability
HbA1c provides an estimate of average glycaemic exposure over several months and is central to assessing long-term metabolic burden and complication risk in Type 2 diabetes. However, it does not capture short-term glucose excursions, dehydration-related hyperglycaemia, or hypoglycaemic episodes, particularly in advanced disease or during acute illness.
As insulin resistance and beta-cell failure progress, metabolic stability becomes increasingly fragile. Infection, corticosteroid use, dehydration, or physiological stress can precipitate severe hyperglycaemia and acute metabolic emergencies, including hyperosmolar hyperglycaemic state. Understanding the underlying pathophysiology explains why Type 2 diabetes functions both as a chronic vascular disorder and as a condition capable of acute metabolic deterioration when compensatory capacity is exceeded.
Concept Check
How does insulin resistance impair glucose uptake at the cellular level?
Why does hepatic glucose production remain elevated in Type 2 diabetes?
How do beta cells initially compensate for insulin resistance?
What mechanisms contribute to progressive beta-cell failure over time?
Why can Type 2 diabetes remain asymptomatic despite ongoing tissue damage?